Angiogenic agent and method of manufacturing the same

EP4706699A3Pending Publication Date: 2026-06-03FUJIFILM CORP
View PDF 9 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
FUJIFILM CORP
Filing Date
2018-08-30
Publication Date
2026-06-03

AI Technical Summary

Technical Problem

Existing methods for using mesenchymal stem cells (MSCs) in regenerative medicine face challenges such as immune rejection and the need for immunosuppressant agents, which come with side effects, limiting their therapeutic efficacy.

Method used

An angiogenic agent is developed using an immunoisolation membrane to enclose mesenchymal stem cells, preventing immune rejection while allowing angiogenesis, comprising a porous membrane with specific pore diameters and thickness, and biocompatible polymer blocks to stabilize and deliver nutrients.

Benefits of technology

The angiogenic agent effectively promotes angiogenesis without immune rejection, creating new blood vessels and providing a long-term therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SREP0001
    Figure SREP0001
  • Figure SREP0002
    Figure SREP0002
  • Figure SREP0003
    Figure SREP0003
Patent Text Reader

Abstract

An object of the present invention is to provide an angiogenic agent that can sufficiently exhibit an angiogenic effect due to mesenchymal stem cells in a state where the angiogenic agent does not allow permeation of host cells while being protected from immune rejection, and a method for method for manufacturing the same. According to the present invention, an angiogenic agent including a mesenchymal stem cell (A); and an immunoisolation membrane (B) that encloses the mesenchymal stem cell is provided.
Need to check novelty before this filing date? Find Prior Art